Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HIMS PEER ANALYSIS

Hims Hers Health Inc — metric-by-metric comparison with peers and the industry median

HIMSHims Hers Health Inc

🇺🇸 USA · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - Specialty & Generic

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
HIMSIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
HIMS-22.5%ROVI+3.7%BHC-26.3%ECILC+66.8%MRK+34.1%GENIL-11.8%
Year-to-Date (YTD)
HIMS+13.3%ROVI-10.4%BHC-27.0%ECILC-5.9%MRK+21.2%GENIL-31.8%
1-Year
Split-adjusted
HIMS-22.5%LQDA+554.5%ALKS+88.2%LNTH+38.0%AMRX+104.9%ELAN+69.8%
Year-to-Date (YTD)
HIMS+13.3%LQDA+128.8%ALKS+95.1%LNTH+65.1%AMRX+36.1%ELAN+10.5%

Key Metric Comparison

P/E

Lower is better
HIMS—ROVI22.08BHC—ECILC—MRK25.00GENIL46.82Median 21.37

ROE

Higher is better
HIMS-2.7%ROVI20.9%BHC—ECILC-0.6%MRK8.5%GENIL8.7%Median 6.4%

Net Margin

Higher is better
HIMS-0.6%ROVI17.8%BHC-13.5%ECILC-3.6%MRK12.1%GENIL4.0%Median 4.0%

Revenue Growth

Higher is better
HIMS32.8%ROVI-3.4%BHC-9.9%ECILC-2.3%MRK-1.7%GENIL16.3%Median 7.5%

P/E

Lower is better
HIMS—LQDA357.80ALKS59.40LNTH25.90AMRX46.10ELAN—Median 21.37

ROE

Higher is better
HIMS-2.7%LQDA28.2%ALKS9.4%LNTH23.5%AMRX—ELAN-3.8%Median 6.4%

Net Margin

Higher is better
HIMS-0.6%LQDA7.7%ALKS9.8%LNTH18.0%AMRX4.0%ELAN-4.9%Median 4.0%

Revenue Growth

Higher is better
HIMS32.8%LQDA1,936.7%ALKS3.2%LNTH0.6%AMRX7.6%ELAN10.5%Median 7.5%

All Metrics

Valuation
MetricHIMSROVIBHCECILCMRKGENILInd. Median
P/E—22.08●——25.0046.8221.37
P/B18.834.32-0.88●0.802.133.471.82
EV/EBITDA292.2714.644.05●33.8411.9914.0712.26
P/S3.553.930.21●5.033.021.862.09
Financial Health
MetricHIMSROVIBHCECILCMRKGENILInd. Median
Current Ratio1.693.66●1.321.731.511.332.22
Debt/Equity253.7%17.0%-1,010.0%●5.9%40.5%41.0%46.3%
NetDebt/EBITDA12.680.093.71-0.10●1.381.101.24
Profitability
MetricHIMSROVIBHCECILCMRKGENILInd. Median
Net Margin-0.6%17.8%●-13.5%-3.6%12.1%4.0%4.0%
ROE-2.7%20.9%●—-0.6%8.5%8.7%6.4%
ROA-0.8%15.1%●-4.7%-0.5%4.9%4.8%3.4%
EBITDA Margin1.3%27.0%60.0%●14.8%28.5%14.3%18.2%
Growth + Dividend
MetricHIMSROVIBHCECILCMRKGENILInd. Median
Rev. Growth32.8%●-3.4%-9.9%-2.3%-1.7%16.3%7.5%
NI Growth—-5.9%——-10.1%146.6%●5.0%
Div. Yield—1.6%0.0%2.6%●1.5%0.0%2.0%
Payout—36.3%0.0%-365.1%11.8%0.0%0.8%
Valuation
MetricHIMSLQDAALKSLNTHAMRXELANInd. Median
P/E—357.8059.4025.90●46.10—21.37
P/B18.8373.505.185.96-124.23●1.951.82
EV/EBITDA292.27147.6536.6915.5613.00●21.2212.26
P/S3.5527.705.814.671.85●2.592.09
Financial Health
MetricHIMSLQDAALKSLNTHAMRXELANInd. Median
Current Ratio1.692.222.272.83●2.472.162.22
Debt/Equity253.7%170.2%90.3%51.6%-5,938.0%●61.4%46.3%
NetDebt/EBITDA12.68-0.71●3.870.273.994.661.24
Profitability
MetricHIMSLQDAALKSLNTHAMRXELANInd. Median
Net Margin-0.6%7.7%9.8%18.0%●4.0%-4.9%4.0%
ROE-2.7%28.2%●9.4%23.5%—-3.8%6.4%
ROA-0.8%7.1%4.8%12.7%●3.5%-1.8%3.4%
EBITDA Margin1.3%18.7%17.7%30.6%●20.6%15.6%18.2%
Growth + Dividend
MetricHIMSLQDAALKSLNTHAMRXELANInd. Median
Rev. Growth32.8%1,936.7%●3.2%0.6%7.6%10.5%7.5%
NI Growth——-56.7%9.7%●——5.0%
Div. Yield——————2.0%
Payout——————0.8%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on HIMS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.